Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2025
Anaplastic Thyroid Carcinoma: A Contemporary Review of Challenges and Advances.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Silver Karcioglu Amanda, Slough Cristian, Jordan Symone V, Brown Taylor D, Kenzie J Reece Mac, Campbell Desiree T, Dennis Daniella, Kinua Amisheila Gloria, Spaulding Sarah L, Goli Ariana, Bible Keith, Freeman Jeremy L, Newbold Kate, Shaha Ashok R, Urken Mark, Zafereo Mark, Abdelhamid Ahmed Amr H, Randolph Gregory W
Аннотация
OBJECTIVE: To review the epidemiology, molecular landscape, diagnostic strategies, and treatment options for anaplastic thyroid carcinoma (ATC), with emphasis on the role of targeted therapy and multimodal care.
METHODS: A comprehensive review of current literature and clinical guidelines was performed, focusing on diagnostic approaches, molecular profiling, and treatment strategies including surgery, radiation, systemic therapy, and emerging targeted and immunotherapies.
RESULTS: ATC represents <2% of thyroid cancers but accounts for over 50% of thyroid-cancer related mortality, with median survival of <1 year. Timely biopsy and molecular testing, particularly for BRAFV600E, allow initiation of targeted therapy. For resectable disease, surgery with adjuvant chemoradiation improves survival. In unresectable or metastatic disease, dabrafenib plus trametinib has significantly improved outcomes in BRAFV600E-mutant ATC, while immunotherapy and other targeted agents show emerging promise.
CONCLUSIONS: Despite advances, ATC remains highly lethal. Early multidisciplinary care centered around individual patient care goals expedited molecular testing, and enrollment in clinical trials are critical to improving survival and guiding future therapeutic strategies.
METHODS: A comprehensive review of current literature and clinical guidelines was performed, focusing on diagnostic approaches, molecular profiling, and treatment strategies including surgery, radiation, systemic therapy, and emerging targeted and immunotherapies.
RESULTS: ATC represents <2% of thyroid cancers but accounts for over 50% of thyroid-cancer related mortality, with median survival of <1 year. Timely biopsy and molecular testing, particularly for BRAFV600E, allow initiation of targeted therapy. For resectable disease, surgery with adjuvant chemoradiation improves survival. In unresectable or metastatic disease, dabrafenib plus trametinib has significantly improved outcomes in BRAFV600E-mutant ATC, while immunotherapy and other targeted agents show emerging promise.
CONCLUSIONS: Despite advances, ATC remains highly lethal. Early multidisciplinary care centered around individual patient care goals expedited molecular testing, and enrollment in clinical trials are critical to improving survival and guiding future therapeutic strategies.